Here’s what you should know.
1. After tweeting the news, pharmaceutical stocks fell, Reuters reported in a tweet.
2. Chicago-based Mylan Pharmaceuticals was harshly criticized in 2016 over its Epi-Pen pricing practices. It stocks was at $43.21 as of 11:30 a.m. on March 7, 2017. It fell 0.6 percent from open.
3. Foster City, Calif.-based Gilead Sciences, whose drug, Solvadi, was also criticized for its pricing practice, opened at $43.45, quickly falling to $42.82 before rebounding to $43.21 at 11:30 a.m. on March 7, 2017.
4. Parsippany-Troy Hills, N.J.-based Allergan, whose CEO committed to limiting price increases to single-digits, saw its stock fell 1.76 percent as of 11:30 a.m. to $237.98. The stocks opened at $239.86 on March 7, 2017.
5. President Trump has yet to reveal the exact plans of his system.
More articles on improving health:
ECRI Institute recommends 8 strategies for safe HIT use in patient identification
Urgent: WHO releases 12 bacteria in need of new antibiotic development
17 tools for patient handoff communications to know | 2017
